FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2588045561> ?p ?o ?g. }

• W2588045561 endingPage "vi385" @default.
• W2588045561 startingPage "vi385" @default.
• W2588045561 abstract "The programmed death receptor 1 (PD-1) inhibitor pembrolizumab has shown clinical benefit with acceptable tolerability in pts with advanced melanoma. We provide detailed information on the safety profile of pembrolizumab in one institution. In the KEYNOTE-001 phase 1 trial, pts with advanced melanoma received either pembrolizumab 10 mg/kg every 2 weeks or 10 mg/kg every 3 weeks or 2 mg/kg every 3 weeks until disease progression or severe toxicity. The severity of the adverse events (AEs) was graded according to the National Cancer Institute Common Terminology Criteria for AEs, version 4.0. AEs were depicted using percentages. The cumulative incidence of AEs from treatment initiation was estimated with the Kaplan-Meier method. 78 pts received pembrolizumab: 2 mg/kg Q3W (n = 20), 10 mg/kg Q2W (n = 23) or 10 mg/kg Q3W (n = 35) in our institution. The median duration of follow-up was 20 months. Treatment was well tolerated, with a similar cumulative incidence of AEs with the 3 pembrolizumab dosing regimens and no drug-related death. AEs of any grade were observed in 73 pts (94%). The most common AEs were fatigue, arthralgia, vitiligo, pruritus and diarrhea. The time to onset of AEs did not differ between the 3 dosing regimens (p > 0.4). The median times to onset of skin disorders and musculoskeletal disorders were 8.3 months and 17.3 months respectively, whereas the median time to onset of gastrointestinal disorders was not reached. Grade 3 or 4 AEs occurred in 11 pts (14%). Permanent discontinuation was reported in 7 pts (9%) due to treatment-related AEs, including colitis, thromboembolic events, pneumonitis, interstitial nephritis and hemolytic anemia. Unexpected AEs were reported, including infections in 31 pts (40%), teeth/gingival abnormalities in 8 pts (10%) and pleural effusion in 3 (4%). Vitiligo was reported in 21 pts (27%) and seemed associated with clinical response. This safety analysis provides a detailed characterization of the AE profile of pembrolizumab, and reports new unanticipated AEs potentially related to the drug." @default.
• W2588045561 created "2017-02-24" @default.
• W2588045561 creator A5001508020 @default.
• W2588045561 creator A5009132075 @default.
• W2588045561 creator A5021121216 @default.
• W2588045561 creator A5022503555 @default.
• W2588045561 creator A5024460514 @default.
• W2588045561 creator A5029587078 @default.
• W2588045561 creator A5030924742 @default.
• W2588045561 creator A5036152103 @default.
• W2588045561 creator A5042234727 @default.
• W2588045561 creator A5045815867 @default.
• W2588045561 creator A5052272801 @default.
• W2588045561 creator A5052579165 @default.
• W2588045561 creator A5056132643 @default.
• W2588045561 creator A5057865336 @default.
• W2588045561 creator A5060793722 @default.
• W2588045561 creator A5072317385 @default.
• W2588045561 creator A5075352950 @default.
• W2588045561 creator A5075840877 @default.
• W2588045561 creator A5084507102 @default.
• W2588045561 creator A5085234192 @default.
• W2588045561 date "2016-10-01" @default.
• W2588045561 modified "2023-09-28" @default.
• W2588045561 title "Detailed safety profile of the anti-PD-1 monoclonal antibody pembrolizumab in 78 consecutive patients (pts) with advanced melanoma" @default.
• W2588045561 doi "https://doi.org/10.1093/annonc/mdw379.19" @default.
• W2588045561 hasPublicationYear "2016" @default.
• W2588045561 type Work @default.
• W2588045561 sameAs 2588045561 @default.
• W2588045561 citedByCount "0" @default.
• W2588045561 crossrefType "journal-article" @default.
• W2588045561 hasAuthorship W2588045561A5001508020 @default.
• W2588045561 hasAuthorship W2588045561A5009132075 @default.
• W2588045561 hasAuthorship W2588045561A5021121216 @default.
• W2588045561 hasAuthorship W2588045561A5022503555 @default.
• W2588045561 hasAuthorship W2588045561A5024460514 @default.
• W2588045561 hasAuthorship W2588045561A5029587078 @default.
• W2588045561 hasAuthorship W2588045561A5030924742 @default.
• W2588045561 hasAuthorship W2588045561A5036152103 @default.
• W2588045561 hasAuthorship W2588045561A5042234727 @default.
• W2588045561 hasAuthorship W2588045561A5045815867 @default.
• W2588045561 hasAuthorship W2588045561A5052272801 @default.
• W2588045561 hasAuthorship W2588045561A5052579165 @default.
• W2588045561 hasAuthorship W2588045561A5056132643 @default.
• W2588045561 hasAuthorship W2588045561A5057865336 @default.
• W2588045561 hasAuthorship W2588045561A5060793722 @default.
• W2588045561 hasAuthorship W2588045561A5072317385 @default.
• W2588045561 hasAuthorship W2588045561A5075352950 @default.
• W2588045561 hasAuthorship W2588045561A5075840877 @default.
• W2588045561 hasAuthorship W2588045561A5084507102 @default.
• W2588045561 hasAuthorship W2588045561A5085234192 @default.
• W2588045561 hasBestOaLocation W25880455611 @default.
• W2588045561 hasConcept C120665830 @default.
• W2588045561 hasConcept C121332964 @default.
• W2588045561 hasConcept C121608353 @default.
• W2588045561 hasConcept C126322002 @default.
• W2588045561 hasConcept C141071460 @default.
• W2588045561 hasConcept C197934379 @default.
• W2588045561 hasConcept C2777288759 @default.
• W2588045561 hasConcept C2777701055 @default.
• W2588045561 hasConcept C2777793932 @default.
• W2588045561 hasConcept C2778375690 @default.
• W2588045561 hasConcept C2778715236 @default.
• W2588045561 hasConcept C2780057760 @default.
• W2588045561 hasConcept C61511704 @default.
• W2588045561 hasConcept C71924100 @default.
• W2588045561 hasConcept C72563966 @default.
• W2588045561 hasConcept C88879693 @default.
• W2588045561 hasConcept C90924648 @default.
• W2588045561 hasConceptScore W2588045561C120665830 @default.
• W2588045561 hasConceptScore W2588045561C121332964 @default.
• W2588045561 hasConceptScore W2588045561C121608353 @default.
• W2588045561 hasConceptScore W2588045561C126322002 @default.
• W2588045561 hasConceptScore W2588045561C141071460 @default.
• W2588045561 hasConceptScore W2588045561C197934379 @default.
• W2588045561 hasConceptScore W2588045561C2777288759 @default.
• W2588045561 hasConceptScore W2588045561C2777701055 @default.
• W2588045561 hasConceptScore W2588045561C2777793932 @default.
• W2588045561 hasConceptScore W2588045561C2778375690 @default.
• W2588045561 hasConceptScore W2588045561C2778715236 @default.
• W2588045561 hasConceptScore W2588045561C2780057760 @default.
• W2588045561 hasConceptScore W2588045561C61511704 @default.
• W2588045561 hasConceptScore W2588045561C71924100 @default.
• W2588045561 hasConceptScore W2588045561C72563966 @default.
• W2588045561 hasConceptScore W2588045561C88879693 @default.
• W2588045561 hasConceptScore W2588045561C90924648 @default.
• W2588045561 hasLocation W25880455611 @default.
• W2588045561 hasOpenAccess W2588045561 @default.
• W2588045561 hasPrimaryLocation W25880455611 @default.
• W2588045561 hasRelatedWork W2079421112 @default.
• W2588045561 hasRelatedWork W2089245388 @default.
• W2588045561 hasRelatedWork W2358624079 @default.
• W2588045561 hasRelatedWork W2792428998 @default.
• W2588045561 hasRelatedWork W2896659597 @default.
• W2588045561 hasRelatedWork W2996750011 @default.
• W2588045561 hasRelatedWork W3138587145 @default.
• W2588045561 hasRelatedWork W3172600265 @default.
• W2588045561 hasRelatedWork W4323044742 @default.

• next